BUSINESS
Seikagaku to Initiate PII/III Clinical Trial of SI-614 for Treatment of Dry Eye in the US
Seikagaku Corporation announced on May 7 that it will initiate a PII/III multicenter, placebo-controlled randomized trial in the US for SI-614, an ophthalmic solution under development as a treatment for dry eye. Clinically meaningful results of the drug were confirmed…
To read the full story
Related Article
- Seikagaku’s Dry Eye Drug Enters PIII in US
May 16, 2022
BUSINESS
- Sanofi Files Dupixent for CSU in Children Aged 2-11 in Japan
December 26, 2025
- Enhertu Wins 5th China Indication in HER2-Low/Ultralow Breast Cancer
December 26, 2025
- SymBio Bags Rights to Develop Antiviral Brincidofovir for Alzheimer’s
December 26, 2025
- Dayvigo Wins Triple Crown in November HP Promotion List: Intage
December 26, 2025
- Pharma Hails End to “Spillover” Rule, Vows to Keep Fighting Off-Year Cuts
December 25, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…





